Skip to main content
SpringerLink
Log in

Urgences et complications iatrogènes chez le patient cancéreux

  • Chapter
Thérapeutique du cancer

  • 773 Accesses

Résumé

Le patient cancéreux peut présenter des complications très diverses liées à son traitement. Ce chapitre, axé sur l’urgence, aura pour objet de mettre en évidence les plus importantes ou les plus spécifiques d’entre elles (à l’exception de celles couvertes ailleurs dans ce livre), le lecteur étant invité à se référer au site web en accès libre www.oncorea.com pour des informations complémentaires, notamment sur les attitudes pratiques.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Wachter RM, Luce JM, Hearst N, Lo B (1989) Decisions about resuscitation: inequities among patients with different diseases but similar prognoses. Ann Intern Med 111: 525–532

    Article  PubMed  CAS  Google Scholar 

  2. Groeger JS, Lemeshow S, Price K et al. (1998) Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model. J Clin Oncol 16: 761–770

    PubMed  CAS  Google Scholar 

  3. Sculier JP, Paesmans M, Markiewicz E, Berghmans T (2000) Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit. Crit Care Med 28: 2786–2792

    Article  PubMed  CAS  Google Scholar 

  4. Azoulay E, Moreau D, Alberti C et al. (2000) Predictors of short-term mortality in critically ill patients with solid malignancies. Intensive Care Med 26: 1817–1823

    Article  PubMed  CAS  Google Scholar 

  5. Staudinger T, Stoiser B, Mullner M et al. (2000) Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit Care Med 28: 1322–1328

    Article  PubMed  CAS  Google Scholar 

  6. Kroschinsky F, Weise M, Illmer T et al. (2002) Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies. Intensive Care Med 28: 1294–1300

    Article  PubMed  Google Scholar 

  7. Massion PB, Dive AM, Doyen C et al. (2002) Prognosis of hematologic malignancies does not predict intensive care unit mortality. Crit Care Med 30: 2260–2270

    Article  PubMed  Google Scholar 

  8. Maschmeyer G, Bertschat FL, Moesta KT et al. (2003) Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period. Eur J Cancer 39: 783–792

    Article  PubMed  CAS  Google Scholar 

  9. Benoit DD, Vandewoude KH, Decruyenaere JM et al. (2003) Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit Care Med 31: 104–112

    Article  PubMed  Google Scholar 

  10. Azoulay E, Afessa B (2006) The intensive care support of patients with malignancy: do everything that can be done. Intensive Care Med 32: 3–5

    Article  PubMed  Google Scholar 

  11. Groeger JS, Glassman J, Nierman DM et al. (2003) Probability of mortality of critically ill cancer patients at 72 h of intensive care unit (ICU) management. Support Care Cancer 11: 686–695

    Article  PubMed  Google Scholar 

  12. Lamia B, Hellot MF, Girault C et al. (2006) Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU. Intensive Care Med 32: 1560–1568

    Article  PubMed  CAS  Google Scholar 

  13. Faber-Langendoen K (1991) Resuscitation of patients with metastatic cancer. Is transient benefit still futile? Arch Intern Med 151: 235–239

    Article  PubMed  CAS  Google Scholar 

  14. Vitelli CE, Cooper K, Rogatko A, Brennan MF (1991) Cardiopulmonary resuscitation and the patient with cancer. J Clin Oncol 9: 111–115

    PubMed  CAS  Google Scholar 

  15. Sculier JP, Markiewicz E (1993) Cardiopulmonary resuscitation in medical cancer patients: the experience of a medical intensive-care unit of a cancer centre. Support Care Cancer 1: 135–138

    Article  PubMed  CAS  Google Scholar 

  16. Varon J, Walsh GL, Marik PE, Fromm RE (1998) Should a cancer patient be resuscitated following an in-hospital cardiac arrest? Resuscitation 36: 165–168

    Article  PubMed  CAS  Google Scholar 

  17. Ewer MS, Kish SK, Martin CG et al. (2001) Characteristics of cardiac arrest in cancer patients as a predictor of survival after cardiopulmonary resuscitation. Cancer 92: 1905–1912

    Article  PubMed  CAS  Google Scholar 

  18. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee (1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis [see comments]. Crit Care Med 20: 864–874

    Article  Google Scholar 

  19. Sculier JP, Bron D, Verboven N, Klastersky J (1988) Multiple organ failure during interleukin-2 administration and LAK cells infusion. Intensive Care Med 14: 666–667

    Article  PubMed  CAS  Google Scholar 

  20. Diana D, Sculier JP (1990) Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancer. Intensive Care Med 16: 167–170

    Article  PubMed  CAS  Google Scholar 

  21. Nurnberger W, Willers R, Burdach S, Gobel U (1997) Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann Hematol 74: 221–224

    Article  PubMed  CAS  Google Scholar 

  22. Haire WD (2002) Multiple organ dysfunction syndrome in hematopoietic stem cell transplantation. Crit Care Med 30(5 Suppl): S257–S262

    Article  PubMed  Google Scholar 

  23. Sculier JP, Weerts D, Klastersky J (1984) Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy. Eur J Cancer Clin Oncol 20: 55–60

    Article  PubMed  CAS  Google Scholar 

  24. Malik I, Hussain M, Yousuf H (2001) Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies. J Infect 42: 120–125

    Article  PubMed  CAS  Google Scholar 

  25. Sculier JP (1995) Indications for intensive care in the management of infections in cancer patients. In: Klastersky J, editor. Infectious complications of cancer. Kluwer Academic Publishers p. 233–244

    Google Scholar 

  26. Ablin AR (1984) Supportive care for children with cancer. Guidelines of the Childrens Cancer Study Group. Managing the problem of hyperleukocytosis in acute leukemia. Am J Pediatr Hematol Oncol 6: 287–290

    Article  PubMed  CAS  Google Scholar 

  27. Dombret H (1993) Syndrome de lyse tumorale aiguë. In: au]Leclercq B, Sculier JP, editors. Réanimation en cancérologie. Paris: Masson, p. 115–129

    Google Scholar 

  28. Ravaud A, Negrier S, Lakdja F et al. (1991) Effets secondaires de l’interleukine 2. Bull Cancer 78: 989–1005

    PubMed  CAS  Google Scholar 

  29. Cahill RA, Spitzer TR, Mazumder A (1996) Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant 18: 177–184

    PubMed  CAS  Google Scholar 

  30. Haire WD, Ruby EI, Gordon BG et al. (1995) Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA 274: 1289–1295

    Article  PubMed  CAS  Google Scholar 

  31. Pene F, Aubron C, Azoulay E et al. (2006) Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports. J Clin Oncol 24: 643–649

    Article  PubMed  Google Scholar 

  32. O’Brien ME, Souberbielle BE (1992) Allergic reactions to cytotoxic drugs—an update. Ann Oncol 3: 605–610

    PubMed  Google Scholar 

  33. Park HY, Suh GY, Jeon K et al. (2008) Outcome and prognostic factors of patients with acute leukemia admitted to the intensive care unit for septic shock. Leuk Lymphoma 49: 1929–1934

    Article  PubMed  Google Scholar 

  34. Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125: 47–58

    Article  PubMed  CAS  Google Scholar 

  35. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Article  PubMed  CAS  Google Scholar 

  36. Martin M, Esteva FJ, Alba E et al. (2009) Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 14: 1–11

    Article  PubMed  CAS  Google Scholar 

  37. Graus F, Rogers LR, Posner JB (1985) Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 64: 16–35

    CAS  Google Scholar 

  38. Saphner T, Tormey DC, Gray R (1991) Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9: 286–294

    PubMed  CAS  Google Scholar 

  39. Barcelo R, Lopez-Vivanco G, Mane JM et al. (2000) Distal ischemic changes related to combination chemotherapy with cisplatin and gemcitabine: description of four cases. Ann Oncol 11: 1191–1194

    Article  PubMed  CAS  Google Scholar 

  40. Lee AY, Levine MN, Baker RI et al. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146–153

    Article  PubMed  CAS  Google Scholar 

  41. Falanga A, Zacharski L (2005) Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 16: 696–701

    Article  PubMed  CAS  Google Scholar 

  42. Kurul S, Saip P, Aydin T (2002) Totally implantable venous-access ports: local problems and extravasation injury. Lancet Oncol 3: 684–692

    Article  PubMed  Google Scholar 

  43. Samaras P, Dold S, Braun J et al. (2008) Infectious port complications are more frequent in younger patients with hematologic malignancies than in solid tumor patients. Oncology 74: 237–244

    Article  PubMed  Google Scholar 

  44. Martino P, Micozzi A, Venditti M et al. (1990) Catheter-related right-sided endocarditis in bone marrow transplant recipients. Rev Infect Dis 12: 250–257

    Article  PubMed  CAS  Google Scholar 

  45. Kasper B, Harter C, Meissner J et al. (2004) Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with highdose ifosfamide? Support Care Cancer 12: 205–207

    Article  PubMed  Google Scholar 

  46. Pelgrims J, De Vos F, Van den B J et al. (2000) Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 82: 291–294

    Article  PubMed  CAS  Google Scholar 

  47. Quoix E, Mornex F, Milleron B, Pauli G (1997) Manifestations respiratoires radio-et chimio-induites. Rev Mal Respir 14: 341–353

    PubMed  CAS  Google Scholar 

  48. Tryka AF, Godleski JJ, Fanta CH (1982) Leukemic cell lysis pneumonopathy. A complication of treated myeloblastic leukemia. Cancer 50: 2763–2770

    Article  PubMed  CAS  Google Scholar 

  49. Metcalf JP, Rennard SI, Reed EC et al. (1994) Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group. Am J Med 96: 327–334

    Article  PubMed  CAS  Google Scholar 

  50. Davila ML (2007) Neutropenic enterocolitis: current issues in diagnosis and management. Curr Infect Dis Rep 9: 116–120

    Article  PubMed  Google Scholar 

  51. Gorschluter M, Mey U, Strehl J et al. (2005) Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 75: 1–13

    Article  PubMed  Google Scholar 

  52. Lassau N, Auperin A, Leclere J et al. (2002) Prognostic value of dopplerultrasonography in hepatic veno-occlusive disease. Transplantation 74: 60–66

    Article  PubMed  Google Scholar 

  53. Attal M, Huguet F, Rubie H et al. (1992) Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 79: 2834–2840

    PubMed  CAS  Google Scholar 

  54. Song JS, Seo JJ, Moon HN et al. (2006) Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children. J Korean Med Sci 21: 897–903

    Article  PubMed  CAS  Google Scholar 

  55. Gluckman E, Jolivet I, Scrobohaci ML et al. (1990) Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 74: 277–281

    Article  PubMed  CAS  Google Scholar 

  56. Simon M, Hahn T, Ford LA et al. (2001) Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 27: 627–633

    Article  PubMed  CAS  Google Scholar 

  57. Mouridsen H, Langer S, Buter J et al. (2007) Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 18: 546–550

    Article  PubMed  CAS  Google Scholar 

  58. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64: 328–340 neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 57: 176–89

    Article  PubMed  CAS  Google Scholar 

  59. Paul M, Soares-Weiser K, Leibovici L (2003) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 326: 1111

    Article  PubMed  CAS  Google Scholar 

  60. Vardakas KZ, Samonis G, Chrysanthopoulou SA et al. (2005) Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 5: 431–439

    Article  PubMed  CAS  Google Scholar 

  61. Clark OA, Lyman GH, Castro AA et al. (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23: 4198–4214

    Article  PubMed  CAS  Google Scholar 

  62. Rebulla P, Finazzi G, Marangoni F et al. (1997) The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med 337: 1870–1875

    Article  PubMed  CAS  Google Scholar 

  63. Bohlius J, Langensiepen S, Schwarzer G et al. (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97: 489–498

    Article  PubMed  CAS  Google Scholar 

  64. Odell WD (1997) Endocrine/metabolic syndromes of cancer. Semin Oncol 24: 299–317

    PubMed  CAS  Google Scholar 

  65. Berghmans T (1996) Hyponatremia related to medical anticancer treatment. Support Care Cancer 4: 341–350

    Article  PubMed  CAS  Google Scholar 

  66. Decaux G, Soupart A (2003) Treatment of symptomatic hyponatremia. Am J Med Sci 326: 25–30

    Article  PubMed  Google Scholar 

  67. Decaux G, Soupart A, Vassart G (2008) Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371: 1624–1632

    Article  PubMed  CAS  Google Scholar 

  68. Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21: 33–64

    Article  PubMed  CAS  Google Scholar 

  69. Berghmans T, Meert AP, Markiewicz E, Sculier JP (2004) Continuous venovenous haemofiltration in cancer patients with renal failure: a single-centre experience. Support Care Cancer 12: 306–311

    Article  PubMed  CAS  Google Scholar 

  70. Darmon M, Thiery G, Ciroldi M et al. (2007) Should dialysis be offered to cancer patients with acute kidney injury? Intensive Care Med 33: 765–772

    Article  PubMed  Google Scholar 

  71. Furlanut M, Franceschi L (2003) Pharmacology of ifosfamide. Oncology 65(Suppl 2):2–6

    Article  PubMed  CAS  Google Scholar 

  72. Akiyama H, Kurosu T, Sakashita C et al. (2001) Adenovirus is a key pathogen in hemorrhagic cystitis associated with bone marrow transplantation. Clin Infect Dis 32: 1325–1330

    Article  PubMed  CAS  Google Scholar 

  73. Dropulic LK, Jones RJ (2008) Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplant 41: 11–18

    Article  PubMed  CAS  Google Scholar 

  74. Russo P (2000) Urologic emergencies in the cancer patient. Semin Oncol 27: 284–298

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité de soins intensifs médicochirurgicaux, Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles, 1 rue Héger-Bordet, B-1000, Bruxelles, Belgique

    J.-P. Sculier, A.-P. Meert & T. Berghmans

Authors
  1. J.-P. Sculier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A.-P. Meert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Berghmans
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France

About this chapter

Cite this chapter

Sculier, JP., Meert, AP., Berghmans, T. (2011). Urgences et complications iatrogènes chez le patient cancéreux. In: Thérapeutique du cancer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0021-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0021-9_9

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0020-2

  • Online ISBN: 978-2-8178-0021-9

Publish with us

Policies and ethics

Search

Navigation